Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Warts-Pipeline Review, H1 2015

Warts-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Warts-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Warts-Pipeline Review, H1 2015', provides an overview of the Warts's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Warts, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Warts and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Warts

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Warts and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Warts products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Warts pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Warts

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Warts pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Warts Overview 8

Therapeutics Development 9

Pipeline Products for Warts-Overview 9

Pipeline Products for Warts-Comparative Analysis 10

Warts-Therapeutics under Development by Companies 11

Warts-Pipeline Products Glance 13

Clinical Stage Products 13

Early Stage Products 14

Warts-Products under Development by Companies 15

Warts-Companies Involved in Therapeutics Development 16

3M Drug Delivery Systems 16

Agilvax, Inc. 17

Anaconda Pharma 18

BioMAS Ltd. 19

Burke Pharmaceuticals, LLC 20

Cutanea Life Sciences 21

Foamix Pharmaceuticals Ltd. 22

G&E Herbal Biotechnology Co., Ltd. 23

Helix BioPharma Corp. 24

NanoViricides, Inc. 25

Nielsen Biosciences, Inc. 26

ViroStatics, srl 27

Warts-Therapeutics Assessment 28

Assessment by Monotherapy Products 28

Assessment by Combination Products 29

Assessment by Target 30

Assessment by Mechanism of Action 32

Assessment by Route of Administration 34

Assessment by Molecule Type 36

Drug Profiles 38

(digoxin + furosemide)-Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

854-A-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

A-101-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

AP-611074-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

AS-101-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

AX-03-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

BURKE-201-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

Candida Albicans Antigen-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

HerpeCide-I-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

imiquimod-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

interferon alpha-2b (recombinant)-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

PP-210-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

Small Molecule to Inhibit CDK9 for HPV Associated Cancers and Warts-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

SRT-100-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

Warts-Recent Pipeline Updates 54

Warts-Dormant Projects 57

Warts-Discontinued Products 58

Warts-Product Development Milestones 59

Featured News & Press Releases 59

Oct 26, 2012: South Africa, first to grant IP protection in anti-warts 59

Dec 22, 2011: Helix BioPharma Files Clinical Trial Applications For Phase III Efficacy Trial Of Topical Interferon Alpha-2b In Patients With Low-Grade Cervical Lesions 59

Jun 08, 2010: Helix BioPharma Corp Announces Phase II Clinical Trial Results of Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 60

Mar 22, 2010: Helix BioPharma Corp Achieves Last-Patient-Out In Its Phase II Trial Of Topical Interferon Alpha-2b In Patients With Ano-Genital Warts 61

Sep 22, 2008: Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts 61

Appendix 62

Methodology 62

Coverage 62

Secondary Research 62

Primary Research 62

Expert Panel Validation 62

Contact Us 63

Disclaimer 63

List of Tables

Number of Products under Development for Warts, H1 2015 9

Number of Products under Development for Warts-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Warts-Pipeline by 3M Drug Delivery Systems, H1 2015 16

Warts-Pipeline by Agilvax, Inc., H1 2015 17

Warts-Pipeline by Anaconda Pharma, H1 2015 18

Warts-Pipeline by BioMAS Ltd., H1 2015 19

Warts-Pipeline by Burke Pharmaceuticals, LLC, H1 2015 20

Warts-Pipeline by Cutanea Life Sciences, H1 2015 21

Warts-Pipeline by Foamix Pharmaceuticals Ltd., H1 2015 22

Warts-Pipeline by G&E Herbal Biotechnology Co., Ltd., H1 2015 23

Warts-Pipeline by Helix BioPharma Corp., H1 2015 24

Warts-Pipeline by NanoViricides, Inc., H1 2015 25

Warts-Pipeline by Nielsen Biosciences, Inc., H1 2015 26

Warts-Pipeline by ViroStatics, srl, H1 2015 27

Assessment by Monotherapy Products, H1 2015 28

Assessment by Combination Products, H1 2015 29

Number of Products by Stage and Target, H1 2015 31

Number of Products by Stage and Mechanism of Action, H1 2015 33

Number of Products by Stage and Route of Administration, H1 2015 35

Number of Products by Stage and Molecule Type, H1 2015 37

Warts Therapeutics-Recent Pipeline Updates, H1 2015 54

Warts-Dormant Projects, H1 2015 57

Warts-Discontinued Products, H1 2015 58

List of Figures

Number of Products under Development for Warts, H1 2015 9

Number of Products under Development for Warts-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Products, H1 2015 14

Assessment by Monotherapy Products, H1 2015 28

Number of Products by Top 10 Targets, H1 2015 30

Number of Products by Stage and Top 10 Targets, H1 2015 31

Number of Products by Top 10 Mechanism of Actions, H1 2015 32

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Top 10 Routes of Administration, H1 2015 34

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 35

Number of Products by Top 10 Molecule Types, H1 2015 36

Number of Products by Stage and Top 10 Molecule Types, H1 2015 37

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

3M Drug Delivery Systems

Agilvax, Inc.

Anaconda Pharma

BioMAS Ltd.

Burke Pharmaceuticals, LLC

Cutanea Life Sciences

Foamix Pharmaceuticals Ltd.

G&E Herbal Biotechnology Co., Ltd.

Helix BioPharma Corp.

NanoViricides, Inc.

Nielsen Biosciences, Inc.

ViroStatics, srl

Warts Therapeutic Products under Development, Key Players in Warts Therapeutics, Warts Pipeline Overview, Warts Pipeline, Warts Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com